Loading...
Market
How will key opinion leaders' recommendations split between Capvaxive and Prevnar 20 by December 31, 2024?
1
Resolution / Starting Odds
Capvaxive preferred • 33%
Prevnar 20 preferred • 33%
No preference • 33%
Surveys and publications from key opinion leaders in the medical field
Story
FDA Approves Merck's 21-Valent Pneumococcal Vaccine Capvaxive for Adults
Jun 17, 2024, 09:24 PM
The U.S. Food and Drug Administration (FDA) has approved Merck's new 21-valent pneumococcal vaccine, Capvaxive, designed to protect adults against 21 strains of pneumococcus bacteria. This vaccine targets eight serotypes of Streptococcus pneumoniae that are not covered by existing pneumococcal vaccines. The approval sets the stage for a competitive battle between Merck and Pfizer in the pneumococcal vaccine market. The vaccine aims to protect against invasive pneumococcal disease and pneumonia. The Advisory Committee on Immunization Practices (ACIP) and the Centers for Disease Control and Prevention (CDC) will provide recommendations on its usage next week.
View original story
Similar markets
Yes • 50%
No • 50%
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
<10% • 25%
10-20% • 25%
20-30% • 25%
>30% • 25%
<$300 million • 25%
$300-500 million • 25%
$500-700 million • 25%
>$700 million • 25%
United States • 25%
European Union • 25%
Japan • 25%
Other • 25%
Pfizer • 25%
Johnson & Johnson • 25%
AstraZeneca • 25%
Other • 25%
Pfizer • 25%
Merck • 25%
Both equally • 25%
Neither • 25%